SPY344.61+1.88 0.55%
DIA283.65+1.68 0.60%
IXIC11,506.01+21.31 0.19%

uniQure Announces Enrollment Of Next Two Patients In Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease

LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today

· 10/13/2020 07:11

LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two additional patient procedures have been completed in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington's disease. The ongoing patient enrollment follows a meeting last month of the trial's independent Data Safety Monitoring Board (DSMB) to review 90-day follow-up data from the first two patients. The DSMB observed no significant safety concerns to prevent further dosing.  The Phase I/II study is a double-blinded, randomized and controlled clinical trial being conducted in the United States. A total of four patients have been enrolled in the study thus far, including two patients treated with AMT-130 and two patients who received imitation surgery.